Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro

Download

index.pdf

Date

2011-11-01

Author

Kankilic, Berna
Bayramlı, Erdal
Kilic, Emine
Dagdeviren, Sezin
Korkusuz, Feza

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

8
views

18
downloads

Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/beta-tricalcium phosphate (PLLA/beta-TCP) composite to control antibiotic release and stimulate bone formation.

Subject Keywords

Orthopedics and Sports Medicine, General Medicine

URI

https://hdl.handle.net/11511/56993

Journal

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

DOI

https://doi.org/10.1007/s11999-011-2082-9

Collections

Graduate School of Natural and Applied Sciences, Article

Citation Formats

B. Kankilic, E. Bayramlı, E. Kilic, S. Dagdeviren, and F. Korkusuz, “Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro,” CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 469, no. 11, pp. 3222–3228, 2011, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/56993.